A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Lymphoma

In brief

This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18 weeks for participants with DLBCL and 24 weeks for participants with FL.

Key facts

Study ID

NCT02257567

Run by

Hoffmann-La Roche

People needed

331

Starts

2014-10-15

Expected to finish

2021-10-21

Last updated by the study team

2022-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed relapsed or refractory FL (Grades 1, 2, or 3a) or relapsed or refractory DLBCL
• If the participant has received prior bendamustine, response duration must have been greater than (>) 1 year (for participants who have relapse disease after a prior regimen)
• At least one bi-dimensionally measurable lesion on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
• Confirmed availability of archival or freshly collected tumor tissue
• The Phase II NF Cohorts (Arms G and H) will be required to submit tissue and pathology report for central pathology review.
• Life expectancy of at least 24 weeks
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Adequate hematological function unless inadequate function is due to underlying disease

You may not qualify if…

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
• Contraindication to bendamustine, rituximab, or obinutuzumab
• Prior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4 weeks or 5 half-lives before Cycle 1 Day 1
• Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to Cycle 1 Day 1
• Ongoing corticosteroid use >30 mg per day prednisone or equivalent, for purposes other than lymphoma symptom control
• Completion of autologous stem cell transplant (SCT) within 100 days prior to Cycle 1 Day 1
• Prior allogeneic SCT
• Eligibility for autologous SCT
• Grade 3b FL
• History of transformation of indolent disease to DLBCL
• Primary or secondary CNS lymphoma
• Current Grade >1 peripheral neuropathy
• Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1 Day 1
• Suspected or latent tuberculosis
• Positive test results for chronic hepatitis B virus (HBV) infection or for hepatitis C virus (HCV) antibody
• Known history of human immunodeficiency virus (HIV) seropositive status or known infection with human T-cell leukemia virus 1 (HTLV-1) virus
• Women who are pregnant or lactating or who intend to become pregnant within a year of the last dose of study treatment in the rituximab cohort or within 18 months of last dose in the obinutuzumab cohort
• Evidence of laboratory abnormalities in standard renal, hepatic, or coagulation function tests
• Treatment with chimeric antigen receptor T-cell therapy within 100 days prior to Cycle 1, Day 1

Where it is running

• Clearview Cancer Institute — Huntsville, Alabama, United States
• City of Hope National Medical Center — Duarte, California, United States
• Univ of Colorado Canc Ctr — Aurora, Colorado, United States
• Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) — Jacksonville, Florida, United States
• Emory Univ Winship Cancer Inst — Atlanta, Georgia, United States
• Joliet Oncology-Hematology; Associates, Ltd. — Joliet, Illinois, United States
• Horizon Oncology Research, Inc. — Lafayette, Indiana, United States
• Weinberg CA Inst Franklin Sq — Baltimore, Maryland, United States
• Regional Cancer Care Associates LLC - Morristown — Morristown, New Jersey, United States
• University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• West Clinic — Germantown, Tennessee, United States
• Swedish Cancer Inst. — Seattle, Washington, United States
• Northwest Medical Specialties — Tacoma, Washington, United States
• Prince of Wales Hospital; Oncology — Randwick, New South Wales, Australia
• Royal Adelaide Hospital — Adelaide, South Australia, Australia
• Adelaide Cancer Centre — Kurralta Park, South Australia, Australia
• Monash Medical Centre; Haematology Research — Clayton, Victoria, Australia
• BCCA-Vancouver Cancer Centre — Vancouver, British Columbia, Canada
• Queen Elizabeth II Health Sciences Centre; Oncology — Halifax, Nova Scotia, Canada
• Hopital Maisonneuve- Rosemont; Oncology — Montreal, Quebec, Canada
• Jewish General Hospital — Montreal, Quebec, Canada
• Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika — Brno, Czechia
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.